Information  X 
Enter a valid email address
  Print      Mail a friend       More announcements

Thursday 13 June, 2019

Winchester MD Ltd

Winchester MD acquires stake in Biotti

RNS Number : 0371C
Winchester MD Limited
13 June 2019




LONDON, June 13th, 2019 - WINCHESTER MD LIMITED ("Winchester" or the "Company") is pleased to announce that it has acquired a minority position in Boston, Massachusetts based private synthetic cannabis company Biotii Technologies Corp.("Biotii"), created and managed by a group of highly qualified MIT and Harvard health care professionals.


Biotii is actively pursuing genetically engineered microorganisms that express cannabinoid profiles identical to those found in nature - at a fraction of the cost of current cannabis production methods. The scalable synthesizing process will enable the manufacture of lesser-known cannabis compounds, as well as well as tetrahydrocannabinol (THC) and cannabidiol (CBD), at materially lower costs when compared to conventional cultivation and extraction processes.


Traditional cultivation of cannabis plants for the purpose of extracting cannabidiolic acid (CBDA),  including medical THC and CBD is a time, labor and resource intensive endeavor that can result in depressed extraction yields of approximately 2.5%. An alternative tool to produce cannabinoids is biosynthetic engineering, where single cell organisms are programmed to synthesize the enzymes for the metabolic pathway that generates cannabinoids from sugars. Biotii intends to leverage a unique system to mass manufacture large quantities of cannabinoids with a smaller environmental footprint than other known methods.


By 2020, the Biotii team intends to establish processes to mass-produce CBD and medical THC in large quantities (in excess of one hundred metric tons per annum) and boast stable, consistent yields with pharmaceutical grade purities, with the lowest production costs in the industry.


Biotii has in recent times significantly advanced its business plans to include the announced investment on 4th April 2019 from ICC International Cannabis Corp. ((CSE: WRLD.U)(FWB: 8K51)(OTC: WLDCF) ("ICC") and the subsequent entry into a design and automation agreement (the "Agreement") with Y Combinator backed Opentrons Labworks Inc. alongside ICC. The Companies will collaborate to architect and construct Canada's first privately owned high-throughput Bioworks Foundry. The Bioworks Foundry will function as a staging ground for Biotii's cannabinoid researchers and organism designers to manufacture and analyze prototype enzyme pathways. The state-of-the-art facility will afford International Cannabis and Biotii the ability to scale its synthesized cannabinoid testing processes in a rapid and cost effective fashion. The announcement details can be found in full at:


Dr Harrold, CEO, is an MIT instructor with expertise in end-to-end bio-lab management. He is also an entrepreneur having started four start-ups, including two funded by the National Science Foundation. Similarly, Biotii's chief product officer Sisi Ni is an MIT trained materials scientist and engineer who was previously named as one of Forbes' 30 under 30's. Biotii has formed key relationships with leading medical research institutions in both the US and China.



"Biotii has a team of professionals from Harvard and MIT who are looking to disrupt the cannabis space by creating cannabinoids from glucose. This technology would significantly reduce the cost of input for our products which ultimately will bring increased shareholder value" said Faz Moshfeghi, CEO and Co-Founder of Winchester.


For more information, please visit


On Behalf of the Board,

Faz Moshfeghi


[email protected]


About Winchester MD Limited

Winchester MD is a vertically integrated European cannabis company based out of London, UK. The Company was founded in 2018 with an initial focus on CBD Wellness through a revenue producing online retail superstore platform HempElf The Company offers a variety of CBD branded products through its on line superstore and continues to develop and market new products in the CBD Wellness category. In 2019 the Company has expanded into other verticals in the cannabis sector with the vision of becoming a global cannabis leader with cultivation, extraction, CBD wellness and research and development. 


This release has not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000. Therefore this release has not been subject to the procedures and controls which would apply if they were made or approved as a financial promotion by an authorised person. This release is not intended to be a financial promotion or offer to the public and the Company is not making an invitation to invest into the share capital of the Company.


Cautionary Note Regarding Forward-Looking Statements: This release includes certain statements and information that may constitute forward-looking information. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, timing, assumptions or expectations of future performance. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or "occur". Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended.


The Regulation Services Provider accepts no responsibility for the adequacy or accuracy of this release.




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

a d v e r t i s e m e n t